Major involvement of Na+-dependent multivitamin transporter (SLC5A6/SMVT) in uptake of biotin and pantothenic acid by human brain capillary endothelial cells

Journal of Neurochemistry

Volumn 134, Issue 1, 2015, Pages 97-112

  Uchida, Yasuo ^a   Ito, Katsuaki ^a   Ohtsuki, Sumio ^b   Kubo, Yoshiyuki ^c   Suzuki, Takashi ^d   Terasaki, Tetsuya ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

biotin; human blood brain barrier; luminal uptake; pantothenic acid; SLC5A6; structure of inhibitor

Indexed keywords

BIOTIN; CARRIER PROTEIN; DICLOFENAC; DOCOSAHEXAENOIC ACID; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; PANTOTHENIC ACID; PHENYLBUTAZONE; PROSTAGLANDIN E2; SODIUM DEPENDENT MULTIVITAMIN TRANSPORTER; THIOCTIC ACID; UNCLASSIFIED DRUG; BIOTIN TRANSPORTER; COTRANSPORTER;

ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CONTROLLED STUDY; DNA MICROARRAY; DRUG UPTAKE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACACA FASCICULARIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEOMICS; ACTIVE TRANSPORT; ANIMAL; BRAIN; CELL CULTURE; CYTOLOGY; HAPLORHINI; METABOLISM; PHYSIOLOGY; PIG; VASCULAR ENDOTHELIUM; VASCULARIZATION;

AGED; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BIOTIN; BLOOD-BRAIN BARRIER; BRAIN; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HAPLORHINI; HUMANS; MALE; PANTOTHENIC ACID; SWINE; SYMPORTERS;

EID: 84935891582     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13092     Document Type: Article

References (29)

1. Benet L. Z., Øie S., and, Schwartz J. B., (1996) Design and optimization of dosage regimens: pharmacokinetic data, in Goodman & Gilman's the Pharmacological Basis of Therapeutics, 9th (, Hardman J. G., Limbird L. E., Molinoff P. B., Ruddon R. W., and, Gilman A. G., eds), pp. 1707-1792, McGraw-Hill, New York.
2. de Carvalho F. D., and, Quick M., (2011) Surprising substrate versatility in SLC5A6: Na+-coupled I- transport by the human Na+/multivitamin transporter (hSMVT). J. Biol. Chem. 286, 131-137.
3. Daberkow R. L., White B. R., Cederberg R. A., Griffin J. B., and, Zempleni J., (2003) Monocarboxylate transporter 1 mediates biotin uptake in human peripheral blood mononuclear cells. J. Nutr. 133, 2703-2706.
4. Geier E. G., Chen E. C., Webb A., Papp A. C., Yee S. W., Sadee W., and, Giacomini K. M., (2013) Profiling solute carrier transporters in the human blood-brain barrier. Clin. Pharmacol. Ther. 94, 636-639.
5. Hoshi Y., Uchida Y., Tachikawa M., Inoue T., Ohtsuki S., and, Terasaki T., (2013) Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J. Pharm. Sci. 102, 3343-3355.
6. Hosoya K., Yamamoto A., Akanuma S., and, Tachikawa M., (2010) Lipophilicity and transporter influence on blood-retinal barrier permeability: a comparison with blood-brain barrier permeability. Pharm. Res. 27, 2715-2724.
7. Ito K., Uchida Y., Ohtsuki S., Aizawa S., Kawakami H., Katsukura Y., Kamiie J., and, Terasaki T., (2011) Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J. Pharm. Sci. 100, 3939-3950.
8. Kamiie J., Ohtsuki S., Iwase R., et al,. (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm. Res. 25, 1469-1483.
9. Kubo Y., Ohtsuki S., Uchida Y., and, Terasaki T., (2015) Quantitative determination of luminal and abluminal membrane distributions of transporters in porcine brain capillaries by plasma membrane fractionation and quantitative targeted proteomics. J. Pharm. Sci. doi: 10.1002/jps.24398. [Epub ahead of print]
10. Noda S., Umezaki H., Yamamoto K., Araki T., Murakami T., and, Ishii N., (1988) Reye-like syndrome following treatment with the pantothenic acid antagonist, calcium hopantenate. J. Neurol. Neurosurg. Psychiatry 51, 582-585.
11. Ohtsuki S., Uchida Y., Kubo Y., and, Terasaki T., (2011) Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. J. Pharm. Sci. 100, 3547-3559.
12. Ohtsuki S., Ikeda C., Uchida Y., et al,. (2013) Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model. Mol. Pharm. 10, 289-296.
13. Ozand P. T., Gascon G. G., Al Essa M., Joshi S., Al Jishi E., Bakheet S., Al Watban J., Al-Kawi M. Z., and, Dabbagh O., (1998) Biotin-responsive basal ganglia disease: a novel entity. Brain 121 (Pt 7), 1267-1279.
14. Park S., and, Sinko P. J., (2005) The blood-brain barrier sodium-dependent multivitamin transporter: a molecular functional in vitro-in situ correlation. Drug Metab. Dispos. 33, 1547-1554.
15. +/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT. Proc. Natl Acad. Sci. USA 103, 7270-7275.
16. Prasad P. D., Wang H., Kekuda R., Fujita T., Fei Y. J., Devoe L. D., Leibach F. H., and, Ganapathy V., (1998) Cloning and functional expression of a cDNA encoding a mammalian sodium-dependent vitamin transporter mediating the uptake of pantothenate, biotin, and lipoate. J. Biol. Chem. 273, 7501-7506.
17. Pugliese A., Beltramo T., and, Torre D., (2008) Reye's and Reye's-like syndromes. Cell Biochem. Funct. 26, 741-746.
18. Schneider C. A., Rasband W. S., and, Eliceiri K. W., (2012) NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671-675.
19. Shimizu S., Miura M., Kawaguchi T., et al,. (1990) A case of Reye's syndrome occurred during administration of calcium hopantenate. Nihon Shokakibyo Gakkai Zasshi 87, 2540-2544.
20. Spector R., and, Johanson C. E., (2007) Vitamin transport and homeostasis in mammalian brain: focus on Vitamins B and E. J. Neurochem. 103, 425-438.
21. Spector R., and, Mock D., (1987) Biotin transport through the blood-brain barrier. J. Neurochem. 48, 400-404.
22. Spector R., Sivesind C., and, Kinzenbaw D., (1986) Pantothenic acid transport through the blood-brain barrier. J. Neurochem. 47, 966-971.
23. Subramanian V. S., Marchant J. S., and, Said H. M., (2006) Biotin-responsive basal ganglia disease-linked mutations inhibit thiamine transport via hTHTR2: biotin is not a substrate for hTHTR2. Am. J. Physiol. Cell Physiol. 291, C851-C859.
24. Terasaki T., Ohtsuki S., Hori S., Takanaga H., Nakashima E., and, Hosoya K., (2003) New approaches to in vitro models of blood-brain barrier drug transport. Drug Discov. Today 8, 944-954.
25. Uchida Y., Ohtsuki S., Katsukura Y., Ikeda C., Suzuki T., Kamiie J., and, Terasaki T., (2011) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 117, 333-345.
26. Uchida Y., Tachikawa M., Obuchi W., Hoshi Y., Tomioka Y., Ohtsuki S., and, Terasaki T., (2013) A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS 10, 21.
27. Viani A., Rizzo G., Carrai M., and, Pacifici G. M., (1992) The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment. Br. J. Clin. Pharmacol. 33, 299-304.
28. Wolf B., (2013) Biotinidase deficiency, in GeneReviews (, Pagon R. A., Adam M. P., Ardinger H. H., Bird T. D., Dolan C. R., Fong C. T., Smith R. J. H., and, Stephens K., eds), [Internet (no page number)], University of Washington, Seattle (WA).
29. Zeng W. Q., Al-Yamani E., Acierno J. S., Jr, Slaugenhaupt S., Gillis T., MacDonald M. E., Ozand P. T., and, Gusella J. F., (2005) Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am. J. Hum. Genet. 77, 16-26.